Início › Leucemia Linfocítica Crônica › Washington

Ensaios clínicos de Leucemia Linfocítica Crônica em Washington

26 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Washington.

Cidades em Washington

Texto oficial do estudo (Inglês)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
e mais 19

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 103, Tacoma

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07582432

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Seattle

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

FHCC Overlake, Bellevue
Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
e mais 7

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Fred Hutchinson Cancer Research Center, Seattle

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Research Center, Seattle

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Fred Hutchinson Cancer Research Center, Seattle

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Fred Hutchinson Cancer Research Center, Seattle
Summit Cancer Centers, Spokane
Northwest Medical Specialties, Tacoma

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Vista Oncology ( Site 5449), Olympia
Medical Oncology Associates, PS ( Site 5406), Spokane

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010), Spokane

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Fred Hutchinson Cancer Research Center, Seattle

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Fred Hutchinson Cancer Center, Seattle

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT07194980

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Medical Oncology Associates, PS, Spokane

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05254743

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Fred Hutch Cancer Center, Seattle

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT06528301

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Medical Oncology Associates - Spokane, Spokane

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT07342478

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium, Seattle

RecrutandoFase 2Voluntários saudáveis bem-vindos

6 Months · Todos os sexos · Atualizado em 29 de mai. de 2026 · NCT04195633

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutch/University of Washington Cancer Consortium, Seattle

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT04941716

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de abr. de 2026 · NCT06839053

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Vista Oncology - East Olympia /ID# 267337, Olympia
Northwest Medical Specialties Tacoma /ID# 266327, Tacoma

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06428019

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Swedish Cancer Institute, Seattle

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Swedish Cancer Institute, Seattle

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Fred Hutchinson Cancer Center, Seattle

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle

RecrutandoFase 2

Idades de 18 a 80 · Todos os sexos · Atualizado em 14 de out. de 2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Swedish Cancer Institute, Seattle

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.